Literature DB >> 17022763

A 5-year (2000-2004) epidemiological survey of Candida and non-Candida yeast species causing vulvovaginal candidiasis in Graz, Austria.

A Paulitsch1, W Weger, G Ginter-Hanselmayer, E Marth, W Buzina.   

Abstract

Vulvovaginal candidasis (VVC) is a common disease. The majority of cases is caused by Candida albicans, but in recent years an increase has been observed in the frequency of non-albicans Candida infections, especially due to C. glabrata and C. tropicalis. The aim of the study was to assess the prevalence of non-albicans Candida infections in patients suffering from VVC. Therefore, the statistical data of culture-confirmed VVC ascertained at the Institute of Hygiene (Medical University Graz) have been studied. Altogether, 10,463 samples from patients with vulvovaginal complaints were analysed in the years 2000-2004, a number of 3184 proved to be culture-positive for yeast. Candida albicans was the most prevalent cause in 87.9% of all cases. Non-albicans Candida yeast were detected in 12.1%, mainly C. glabrata and Saccharomyces cerevisiae. During a 1-year period 185 patients showed more than one episode of VVC. Patients aged 21-40 years were significantly more prone to suffer from VVC compared with other age-related groups.

Entities:  

Mesh:

Year:  2006        PMID: 17022763     DOI: 10.1111/j.1439-0507.2006.01284.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  26 in total

1.  Saccharomyces cerevisiae vaginitis: microbiology and in vitro antifungal susceptibility.

Authors:  María Julia Echeverría-Irigoyen; Elena Eraso; Josep Cano; María Gomáriz; Josep Guarro; Guillermo Quindós
Journal:  Mycopathologia       Date:  2011-03-22       Impact factor: 2.574

2.  Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013).

Authors:  W Mendling; K Friese; I Mylonas; E-R Weissenbacher; J Brasch; M Schaller; P Mayser; I Effendy; G Ginter-Hanselmayer; H Hof; O Cornely; M Ruhnke
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-04       Impact factor: 2.915

Review 3.  Candida infections of the genitourinary tract.

Authors:  Jacqueline M Achkar; Bettina C Fries
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

4.  Susceptibility pattern of various azoles against Candida species causing vulvovaginal candidiasis.

Authors:  Preeti G Dharmik; A V Gomashe; V G Upadhyay
Journal:  J Obstet Gynaecol India       Date:  2012-11-02

Review 5.  Antifungal drug discovery through the study of invertebrate model hosts.

Authors:  R Pukkila-Worley; E Holson; F Wagner; E Mylonakis
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

6.  Evolutionary divergence in the fungal response to fluconazole revealed by soft clustering.

Authors:  Dwight Kuo; Kai Tan; Guy Zinman; Timothy Ravasi; Ziv Bar-Joseph; Trey Ideker
Journal:  Genome Biol       Date:  2010-07-23       Impact factor: 13.583

7.  Characterization of plant-derived saponin natural products against Candida albicans.

Authors:  Jeffrey J Coleman; Ikechukwu Okoli; George P Tegos; Edward B Holson; Florence F Wagner; Michael R Hamblin; Eleftherios Mylonakis
Journal:  ACS Chem Biol       Date:  2010-03-19       Impact factor: 5.100

8.  Comparison of nucleic acid amplification assays with BD affirm VPIII for diagnosis of vaginitis in symptomatic women.

Authors:  Charles P Cartwright; Bryndon D Lembke; Kalpana Ramachandran; Barbara A Body; Melinda B Nye; Charles A Rivers; Jane R Schwebke
Journal:  J Clin Microbiol       Date:  2013-08-28       Impact factor: 5.948

9.  Epidemiology and antifungal susceptibilities of yeasts causing vulvovaginitis in a teaching hospital.

Authors:  Soledad Gamarra; Susana Morano; Catiana Dudiuk; Estefanía Mancilla; María Elena Nardin; Emilce de Los Angeles Méndez; Guillermo Garcia-Effron
Journal:  Mycopathologia       Date:  2014-07-09       Impact factor: 2.574

10.  Use of antifungal saponin SC-2 of Solanum chrysotrichum for the treatment of vulvovaginal candidiasis: in vitro studies and clinical experiences.

Authors:  Armando Herrera-Arellano; Edgar O López-Villegas; Aida V Rodríguez-Tovar; Alejandro Zamilpa; Enrique Jiménez-Ferrer; Jaime Tortoriello; M Angeles Martínez-Rivera
Journal:  Afr J Tradit Complement Altern Med       Date:  2013-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.